126 related articles for article (PubMed ID: 1588505)
1. Physiological pharmacokinetic parameters for cis-dichlorodiammineplatinum(II) (DDP) in the mouse.
King FG; Dedrick RL
J Pharmacokinet Biopharm; 1992 Feb; 20(1):95-9. PubMed ID: 1588505
[No Abstract] [Full Text] [Related]
2. Physiological pharmacokinetic modeling of cis-dichlorodiammineplatinum(II) (DDP) in several species.
King FG; Dedrick RL; Farris FF
J Pharmacokinet Biopharm; 1986 Apr; 14(2):131-55. PubMed ID: 3746636
[TBL] [Abstract][Full Text] [Related]
3. Selectivity and stereospecificity of the reactions of dichlorodiammineplatinum(II) with three purified plasma proteins.
Pizzo SV; Swaim MW; Roche PA; Gonias SL
J Inorg Biochem; 1988 May; 33(1):67-76. PubMed ID: 2454291
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic study of cis-dichlorodiammineplatinum(II) (DDP) in the beagle dog: thermodynamic and kinetic behavior of DDP in a biologic millieu.
LeRoy AF; Lutz RJ; Dedrick RL; Litterst CL; Guarino AM
Cancer Treat Rep; 1979 Jan; 63(1):59-71. PubMed ID: 421234
[No Abstract] [Full Text] [Related]
5. Cis-diamminedichloroplatinum (II)-procaine pharmacokinetic interaction in mice bearing P388 leukemia.
Esposito M; Vannozzi MO; Viale M; Pellecchia C; Merlo F; Cadoni A; Cafaggi S; Parodi B; Lerza R; Poirier MC
Anticancer Res; 1993; 13(5A):1511-6. PubMed ID: 8239529
[TBL] [Abstract][Full Text] [Related]
6. [High-performance liquid chromatography-based determination of plasma and renal tissue cisplatin levels after subcutaneous cisplatin implantation in mice].
Li WF; Niu XF; Fan T; Wang XP; Liu YL; Chen TN
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Feb; 30(2):242-4. PubMed ID: 20159690
[TBL] [Abstract][Full Text] [Related]
7. Renal handling of cisplatin: interactions with organic anions and cations in the dog.
Klein J; Bentur Y; Cheung D; Moselhy G; Koren G
Clin Invest Med; 1991 Oct; 14(5):388-94. PubMed ID: 1742916
[TBL] [Abstract][Full Text] [Related]
8. Interaction of cis- and trans-diamminedichloroplatinum with metallothionein in vivo.
Zhang B; Huang H; Tang W
J Inorg Biochem; 1995 Apr; 58(1):1-8. PubMed ID: 7738537
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin pharmacokinetics: applications of a physiological model.
Farris FF; Dedrick RL; King FG
Toxicol Lett; 1988 Oct; 43(1-3):117-37. PubMed ID: 3051521
[TBL] [Abstract][Full Text] [Related]
10. Metallothionein induction in mouse tissues by cis-dichlorodiammineplatinum(II) and its hydrolysis products.
Farnworth PG; Hillcoat BL; Roos IA
Chem Biol Interact; 1989; 69(4):319-32. PubMed ID: 2731304
[TBL] [Abstract][Full Text] [Related]
11. Reduction of cis-dichlorodiammineplatinum(II) caused nephrotoxicity by indazolone carboxylic acid.
Radacić M; Boranić M; Skarić D; Skarić V; Mihalić H; Gajsak V; Jercić J; Lelieveld P
Oncology; 1987; 44(1):34-7. PubMed ID: 3561926
[TBL] [Abstract][Full Text] [Related]
12. Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia.
Howell SB; Taetle R
Cancer Treat Rep; 1980; 64(4-5):611-6. PubMed ID: 7191778
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of cis-dichlorodiammine platinum (II) during plasmapheresis.
Hosokawa S; Mizuno H; Abe R; Yoshida O
Artif Organs; 1989 Oct; 13(5):442-6. PubMed ID: 2803054
[TBL] [Abstract][Full Text] [Related]
14. Liposomes as drug carrier system for cis-diamminedichloroplatinum (II). II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution.
Steerenberg PA; Storm G; de Groot G; Claessen A; Bergers JJ; Franken MA; van Hoesel QG; Wubs KL; de Jong WH
Cancer Chemother Pharmacol; 1988; 21(4):299-307. PubMed ID: 3370737
[TBL] [Abstract][Full Text] [Related]
15. Effect of para-aminobenzoic acid on the pharmacokinetics and urinary excretion of cis-diamminedichloroplatinum(II) in rats.
Esposito M; Vannozzi M; Viale M; Pellecchia C; Civalleri D; Gogioso L
Anticancer Res; 1995; 15(6B):2541-7. PubMed ID: 8669820
[TBL] [Abstract][Full Text] [Related]
16. The binding of cis-dichlorodiammineplatinum(II) to extracellular and intracellular compounds in relation to drug uptake and cytotoxicity in vitro.
Melvik JE; Dornish JM; Pettersen EO
Br J Cancer; 1992 Aug; 66(2):260-5. PubMed ID: 1503898
[TBL] [Abstract][Full Text] [Related]
17. A modified pharmacokinetic model for platinum disposition in ovarian cancer patients receiving cisplatin.
Griffiths H; Shelley MD; Fish RG
Eur J Clin Pharmacol; 1987; 33(1):67-72. PubMed ID: 3691598
[TBL] [Abstract][Full Text] [Related]
18. Effect of a forced diuresis on the distribution and excretion (via urine and bile) of 195mplatinum when given as 195mplatinum cis-dichlorodiammineplatinum(II).
DeSimone PA; Yancey RS; Coupal JJ; Butts JD; Hoeschel JD
Cancer Treat Rep; 1979 Jun; 63(6):951-60. PubMed ID: 466654
[TBL] [Abstract][Full Text] [Related]
19. The in vitro binding kinetics of cisplatin to human plasma proteins is not affected by glutathione.
Torti L; Bernareggi A; Castoldi D; Formento ML; Cesarini R; Tognella S
Boll Chim Farm; 1997 Apr; 136(4):301-3. PubMed ID: 9281890
[No Abstract] [Full Text] [Related]
20. [Neutron activation analysis in modelling the elimination from the kidneys of cis-dichlorodiammineplatinum].
Brovtsyn VK
Med Radiol (Mosk); 1986 Feb; 31(2):42-5. PubMed ID: 3951347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
